Pediatric GLP-1 Review: Effects and Safety

A 2026 systematic review found that GLP-1 receptor agonists improved weight outcomes in pediatric obesity and glucose control in youth-onset type 2 diabetes, but the effect depended on the medicine and the condition being treated. The review covered seven randomized trials and six meta-analyses involving 901 participants aged 6 to under 18. It identified semaglutide as producing the largest BMI reduction among the obesity studies it assessed. Gastrointestinal events were the most frequent adverse effects. The authors called for longer follow-up on cardiovascular safety and on bone and growth outcomes^[1].

What the review included

The authors searched PubMed-indexed research published from 2000 through 2025. Their question crossed two related but distinct clinical settings: obesity and type 2 diabetes in children and adolescents. That distinction matters. Obesity trials usually focus on BMI or body weight, while diabetes trials often focus on glycated hemoglobin, or HbA1c, as a measure of average glucose control^[1]. A medicine can improve one endpoint without producing the same pattern on the other.

The review's abstract describes semaglutide 2.4 mg weekly as producing the greatest BMI reduction in adolescents with obesity. It places liraglutide 3.0 mg daily next, noting improvement in BMI standard-deviation score in adolescents and younger children. These are doses reported in the reviewed literature, not instructions for an individual child. Eligibility, approved use, monitoring, and product information must be assessed by a qualified pediatric clinician^[1].

The obesity result behind the semaglutide finding

STEP TEENS helps show what sits behind the review's obesity conclusion. The randomized trial enrolled 201 adolescents aged 12 to under 18, almost all with obesity. Both groups received lifestyle intervention. After 68 weeks, mean BMI changed by minus 16.1% with semaglutide and plus 0.6% with placebo, an estimated difference of minus 16.7 percentage points^[2]. The result is a group average from one adolescent trial. It is not a prediction for every young person and should not be extended automatically to younger children.

The same trial reported that 73% of assessed semaglutide participants and 18% of placebo participants lost at least 5% of body weight. Cardiometabolic measures also moved in a favorable direction for several endpoints, including waist circumference, HbA1c, most reported lipids, and alanine aminotransferase^[2]. Those secondary findings support the review's metabolic framing, but they do not establish long-term prevention of cardiovascular disease or other later outcomes.

Diabetes trials answer a different question

For youth-onset type 2 diabetes, the systematic review reports improved HbA1c with liraglutide and dulaglutide compared with placebo^[1]. The liraglutide ELLIPSE trial illustrates that evidence. It randomized 135 participants aged 10 to under 17. All received metformin, and some also received basal insulin. At 26 weeks, mean HbA1c fell by 0.64 percentage points with liraglutide and rose by 0.42 points with placebo, an estimated treatment difference of minus 1.06 percentage points^[3].

That diabetes result should not be compared directly with the percentage BMI change in STEP TEENS. The populations, background treatments, endpoints, medicine doses, and follow-up periods differed. The review brings those studies together to describe the pediatric GLP-1 evidence base, but it does not turn distinct trials into a head-to-head ranking across obesity and diabetes. Readers can use the semaglutide research overview for broader context on one medicine while keeping the indication-specific evidence separate.

Safety signals in the review

Across the review, nausea and vomiting were the most frequent adverse events. The authors describe gastrointestinal events as generally transient and dose dependent. They also report that the included evidence found no significant adverse effects on linear growth or pubertal progression^[1]. That wording is reassuring within the available studies, but it is not proof that uncommon or delayed developmental effects have been excluded.

The individual trials add scale to that summary. In STEP TEENS, gastrointestinal events occurred in 62% of semaglutide participants and 42% of placebo participants. Five semaglutide participants had cholelithiasis, compared with none receiving placebo; serious adverse events occurred in 11% and 9%, respectively^[2]. In ELLIPSE, the proportion of participants reporting any adverse event was similar between groups, but overall event rates and gastrointestinal event rates were higher with liraglutide^[3]. These findings need clinical interpretation, not a class-wide claim that every product has the same safety profile.

What we don't yet know

The review concludes that GLP-1 receptor agonists can be effective adjuncts in pediatric obesity and type 2 diabetes. Adjunct is important: the trials used background lifestyle care, metformin, or insulin according to the population and protocol. The review also identifies longer-term cardiovascular safety, bone health, and growth as unresolved areas^[1]. A lack of a significant growth or puberty signal in the available follow-up does not answer what years of treatment across development might show.

The evidence base is also not uniform across ages. The largest quantified semaglutide result discussed here came from adolescents aged 12 to under 18, while the review's full age range began at 6. Results from adolescents cannot simply be assigned to younger children. Questions about treatment duration, outcomes after stopping, rare adverse events, and benefits beyond intermediate measures need longer and larger studies. The semaglutide safety section and regulation overview provide additional context, but they do not replace pediatric assessment.

How to read this review

The useful conclusion is narrower than either enthusiasm or alarm. Randomized pediatric evidence shows meaningful BMI reduction with semaglutide in adolescents with obesity and better glucose control with liraglutide in youth with type 2 diabetes. The systematic review finds gastrointestinal adverse effects to be the recurring short-term safety issue and flags important long-term gaps. Families considering a GLP-1 medicine should discuss diagnosis, age, approved options, contraindications, concurrent care, and monitoring with a qualified pediatric clinician.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.